Companies Fortrea Holdings Inc.
Fortrea (FTRE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Fortrea Holdings Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers67th pct.Of 18 peer CEOs
CEO pay, last three years
- $11,584,483FY2025
CEO total pay was $11,584,483 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $401,923 · bonus $0 · stock awards $10,479,169 · option awards $0
Executives and directors
Anshul Thakral · CEOPeter Neupert · ExecutiveMark Morais · PresidentThomas Pike · Chief Executive OfficerJill McConnell · CFODavid Smith · Independent DirectorDr. Amrit Ray · Independent DirectorEdward Pesicka · Independent DirectorErin L. Russell · Independent DirectorMachelle Sanders · Independent DirectorR. Andrew Eckert · Former director (through FY2025)William Sharbaugh · Independent Director
Frequently asked questions
Who was the highest-paid executive at Fortrea Holdings Inc. in fiscal 2025?
As disclosed, Anshul Thakral (Chief Executive Officer and Director) was the highest-paid executive at Fortrea Holdings Inc. in fiscal 2025, with total compensation of $11,584,483.
How does Fortrea Holdings Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Anshul Thakral's total compensation ranked at the 67th percentile of Fortrea Holdings Inc.'s disclosed peer group.
What is Fortrea Holdings Inc.'s CEO-to-median employee pay ratio?
As disclosed, Fortrea Holdings Inc.'s CEO-to-median employee pay ratio was 196:1.
How did shareholders vote on Fortrea Holdings Inc.'s executive compensation?
As disclosed, 94.82% of shareholders supported Fortrea Holdings Inc.'s executive compensation in the latest say-on-pay vote.
How much does Fortrea Holdings Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Fortrea Holdings Inc. reported total board compensation of $1,867,466 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Anshul Thakral | $401,923 | $0 | $10,479,169 | $0 | $687,500 | $0 | $15,891 | $11,584,483 |
| Chief Executive Officer and Director | ||||||||
| Thomas Pike | 465,385 | 0 | 0 | 0 | 0 | 0 | 7,326,338 | 7,791,722 |
| Former Chief Executive Officer | ||||||||
| Jill McConnell | 506,577 | 0 | 862,994 | — | 295,202 | 0 | 16,100 | 1,680,873 |
| Chief Financial Officer | ||||||||
| Mark Morais | 506,577 | 0 | 804,121 | 0 | 295,202 | 0 | 10,888 | 1,616,788 |
| Chief Operating Officer and President, Clinical Services | ||||||||
| Peter Neupert | 389,423 | 0 | 710,000 | 0 | 0 | 0 | 45,838 | 1,145,261 |
| Chairman and Former Interim Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Anshul Thakral | $11,584,483 | — | — | — |
| Thomas Pike | 7,791,722 | 1,713,906 | 26,320,395 | ↑ +6,077,816 |
| Jill McConnell | 1,680,873 | 1,342,017 | 3,078,275 | ↑ +338,856 |
| Mark Morais | 1,616,788 | 1,336,761 | — | ↑ +280,027 |
| Peter Neupert | 1,145,261 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The MDCC's compensation philosophy is to appropriately recognize and reward executives for both Company and individual performance. The MDCC generally believes that it is important to place more emphasis on pay that is performance-based and at-risk, and that pay mix should be more heavily weighted toward variable compensation.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jill McConnell | PSU | 2025-03-20 | 1,908 | 3,816 | — | 7,632 | $26,979 |
| Mark Morais | PSU | 2025-03-20 | 1,908 | 3,816 | — | 7,632 | 26,979 |
| Peter Neupert | RSU | 2025-05-14 | — | — | 148,536 | — | 710,000 |
| Thomas Pike | RSU | 2025-03-20 | — | — | 67,731 | — | 594,000 |
| Anshul Thakral | PSU | 2025-08-04 | 208,333 | 416,667 | — | 833,333 | 2,454,169 |
| Jill McConnell | PSU | 2025-03-20 | 11,890 | 23,780 | — | 47,561 | 193,331 |
| Mark Morais | PSU | 2025-03-20 | 10,865 | 21,730 | — | 43,461 | 176,665 |
| Anshul Thakral | RSU | 2025-08-04 | — | — | 1,250,000 | — | 8,025,000 |
| Jill McConnell | RSU | 2025-03-06 | — | — | 14,313 | — | 153,006 |
| Mark Morais | RSU | 2025-03-06 | — | — | 14,313 | — | 153,006 |
| Jill McConnell | RSU | 2025-03-07 | — | — | 45,850 | — | 489,678 |
| Mark Morais | RSU | 2025-03-07 | — | — | 41,898 | — | 447,471 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jill McConnell | $642,684 | $220,310 | $0 | 25.5% |
| Mark Morais | 600,477 | 203,644 | 0 | 25.3% |
| Peter Neupert | 710,000 | 0 | 0 | 0.0% |
| Thomas Pike | 594,000 | 0 | 0 | 0.0% |
| Anshul Thakral | 8,025,000 | 2,454,169 | 0 | 23.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jill McConnell | RSU | 1,685 | — | $29,066 |
| Mark Morais | RSU | 2,255 | — | 38,899 |
| Jill McConnell | RSU | 7,157 | — | 123,458 |
| Mark Morais | RSU | 7,157 | — | 123,458 |
| Jill McConnell | RSU | 8,568 | — | 147,798 |
| Mark Morais | RSU | 8,568 | — | 147,798 |
| Jill McConnell | RSU | 11,006 | — | 189,854 |
| Mark Morais | RSU | 11,006 | — | 189,854 |
| Jill McConnell | RSU | 11,313 | — | 195,149 |
| Mark Morais | RSU | 11,313 | — | 195,149 |
| Jill McConnell | PSU | 15,264 | — | 263,304 |
| Mark Morais | PSU | 15,264 | — | 263,304 |
| Mark Morais | RSU | 41,898 | — | 722,741 |
| Mark Morais | PSU | 43,461 | — | 749,702 |
| Jill McConnell | RSU | 45,850 | — | 790,913 |
| Jill McConnell | PSU | 47,560 | — | 820,410 |
| Peter Neupert | RSU | 148,536 | — | 2,562,246 |
| Anshul Thakral | PSU | 833,333 | — | 14,375,000 |
| Anshul Thakral | RSU | 1,250,000 | — | 21,562,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Erin L. RussellIndependent · Audit · Nominating, Corporate Governance and Compliance · Newly elected | $82,500 | $420,000 | $0 | $0 | $0 | $502,500 |
| Dr. Amrit RayIndependent · Management Development and Compensation (Chair) · Nominating, Corporate Governance and Compliance | 130,000 | 210,000 | 0 | 0 | 0 | 340,000 |
| David SmithIndependent · Audit (Chair) · Management Development and Compensation | 107,466 | 210,000 | 0 | 0 | 0 | 317,466 |
| Machelle SandersIndependent · Management Development and Compensation · Nominating, Corporate Governance and Compliance (Chair) | 100,000 | 210,000 | 0 | 0 | 0 | 310,000 |
| Edward PesickaIndependent · Audit · Management Development and Compensation | 90,000 | 210,000 | 0 | 0 | 0 | 300,000 |
| R. Andrew EckertIndependent · Departed during FY | 75,000 | 0 | 0 | 0 | 0 | 75,000 |
| William SharbaughIndependent · Audit · Management Development and Compensation · Nominating, Corporate Governance and Compliance · Newly elected | 22,500 | 0 | 0 | 0 | 0 | 22,500 |
| Anshul ThakralEmployee director · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Thomas PikeNot independent · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
| Peter M. NeupertIndependent · Board Chair · Nominating, Corporate Governance and Compliance | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $210,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | 5x annual base salary (CEO: 6x; Other NEOs: 3x) |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $607,466 |
| Equity awards (grant-date value) | $1,260,000 |
| All other compensation | $0 |
| Total cost of the board | $1,867,466 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Fortrea as a peer
Companies that benchmark against FTRE
3 companies name FTRE as a compensation peer
The list of companies that name FTRE as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
OGN Organon & Co.BLCO Bausch + Lomb CorporationCRL Charles River Laboratories International, Inc.EXEL Exelixis, Inc.IART Integra LifeSciencesBIO Bio-Rad LaboratoriesJAZZ Jazz Pharmaceuticals plcXRAY DENTSPLY SIRONA Inc.ENOV Enovis CorporationSHC Sotera Health CompanyTFX Teleflex IncorporatedALKS Alkermes plcBRKR Bruker CorporationCNMD CONMED CorporationHAE Haemonetics CorporationMEDP Medpace Holdings, Inc.PRGO Perrigo Company plcQDEL QuidelOrtho Corporation
Peer reciprocity
The companies Fortrea Holdings Inc. names as compensation peers that name it back in their own disclosed peer groups.
Charles River Laboratories International, Inc. (CRL)101Medpace Holdings, Inc. (MEDP)102QuidelOrtho Corporation (QDEL)103
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Bausch + Lomb Corporation | 2025 | Brenton Saunders | 1,600,000 | 23,778,578 | 2,799,998 | 4,000,000 | 32,194,326 |
| 3 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 4 | Organon & Co. | 2025 | Kevin Ali | 1,088,462 | 10,251,989 | 3,249,999 | 0 | 15,813,296 |
| 5 | Charles River Laboratories International, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 6 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 7 | Fortrea Holdings Inc. | 2025 | Anshul Thakral | 401,923 | 10,479,169 | 0 | 687,500 | 11,584,483 |
| 8 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 9 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 10 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 11 | Integra LifeSciences | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 12 | Enovis Corporation | 2025 | Damien McDonald | 634,615 | 7,262,644 | 0 | 812,749 | 9,242,161 |
| 13 | Perrigo Company plc | 2025 | Patrick Lockwood-Taylor | 1,223,333 | 6,990,564 | 0 | 687,250 | 9,042,603 |
| 14 | Dentsply Sirona Inc. | 2025 | Daniel Scavilla | 431,753 | 3,484,488 | 3,221,523 | 437,150 | 8,760,139 |
| 15 | Bio-Rad Laboratories | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 16 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 17 | Conmed Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 18 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 19 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Fortrea Holdings Inc. | 68.5% | PSU 50 · RSU 50 | No | Pay Governance LLC |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Bausch + Lomb Corporation | 100% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pay Governance |
| Bio-Rad Laboratories | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Charles River Laboratories International, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance, LLC |
| Conmed Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Dentsply Sirona Inc. | 66% | PSU 50 · Options 50 | No | Frederic W. Cook & Co., Inc. |
| Enovis Corporation | 92.2% | PSU 50 · RSU 50 | Yes — Relative TSR vs. S&P 500 Health Care Equipment Select Industry Index | FW Cook |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Integra LifeSciences | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Organon & Co. | 72% | PSU 50 · RSU 25 · Options 25 | Yes — Three-Year Relative TSR | Korn Ferry |
| Perrigo Company plc | 44.3% | PSU 70 · RSU 30 | Yes — Relative TSR (rTSR) | Frederic W. Cook & Company, Inc. |
| QuidelOrtho Corporation | not disclosed | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity, LLP |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 73,544,293 | 3,877,113 | 140,980 | 94.82% | Passed |
| 2025 | 2025-04-17 | 68,050,281 | 3,302,818 | 182,520 | 95.13% | Passed |
| 2024 | 2024-05-14 | 71,701,466 | 6,512,815 | 63,012 | 91.67% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 94.82%a |
| 2025 | 2025-04-17 | 95.13%b |
| 2024 | 2024-05-14 | 91.67%c |
a. Approved under the standard stated in the filing — “Abstentions have the same effect as votes against the ratification of the appointment of Deloitte & Touche LLP, or the Say-on-Pay Vote.”.
b. Approved under the standard stated in the filing — “Abstentions have the same effect as votes against the ratification of the appointment of Deloitte & Touche LLP, the Say-on-Pay Vote or the approval of the A&R Incentive Plan.”.
c. Approved under the standard stated in the filing — “Abstentions have the same effect as votes against the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 196 : 1 |
|---|---|
| CEO total compensation | $12,282,560 |
| Median employee compensation | $62,683 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Peter M. Neupert | Director | 2026-05-14 | D | 148,536 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Peter M. Neupert | Director | 2026-05-14 | A | 148,536 | 0 | 0 | Common | Form 4 ↗ |
| Robert Parks | Chief Accounting Officer | 2026-05-18 | D | 2,000 | 13 | 26,880 | Common | Form 4 ↗ |
| Jill McConnell | Chief Financial Officer | 2026-06-01 | D | 11,006 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jill McConnell | Chief Financial Officer | 2026-06-01 | A | 11,006 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-01 | D | 11,006 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-01 | A | 11,006 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-02 | D | 4,866 | 15 | 75,374 | Common | Form 4 ↗ |
| Jill McConnell | Chief Financial Officer | 2026-06-02 | D | 4,866 | 15 | 75,374 | Common | Form 4 ↗ |
| Erin L. Russell | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erin L. Russell | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erin L. Russell | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Dr. Amrit Ray | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Amrit Ray | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-10 | D | 4,674 | 17 | 78,617 | Common | Form 4 ↗ |
| Edward Pesicka | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Pesicka | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | D | 18,244 | 16 | 298,107 | Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| William Sharbaugh | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Amrit Ray | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Pesicka | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter M. Neupert | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-07-20 | A | 6,598 | 0 | 0 | Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-08-03 | D | 9,700 | 18 | 174,697 | Common | Form 4 ↗ |
| David Smith | Director | 2026-08-03 | A | 15,840 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-04 | D | 416,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-04 | A | 416,666 | 0 | 0 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-05 | D | 50,417 | 19 | 972,040 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-05 | D | 49,452 | 19 | 941,072 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-06 | D | 55,975 | 18 | 1,010,909 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-06 | D | 55,882 | 18 | 1,015,376 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-08-18 | D | 11,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-08-18 | A | 11,313 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-08-19 | D | 4,892 | 18 | 88,985 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-09-08 | D | 7,157 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-09-08 | A | 7,157 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-08 | — | 850 | — | — | 1 insider, 1 accrual row | ||
| Erin L. Russell | Interim CAO | 2026-09-08 | A | 850 | 0 | 0 | Common | Form 4 ↗ |
| Erin L. Russell | Interim CAO | 2026-09-09 | D | 246 | 17 | 4,145 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-09-09 | D | 3,149 | 17 | 53,061 | Common | Form 4 ↗ |
| Jason Fredrick Knoblauch | Chief Financial Officer | 2026-09-10 | A | 144,434 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 47 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Peter M. Neupert | Director | 2026-05-14 | D | 148,536 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Peter M. Neupert | Director | 2026-05-14 | A | 148,536 | 0 | 0 | Common | Form 4 ↗ |
| Robert Parks | Chief Accounting Officer | 2026-05-18 | D | 2,000 | 13 | 26,880 | Common | Form 4 ↗ |
| Jill McConnell | Chief Financial Officer | 2026-06-01 | D | 11,006 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jill McConnell | Chief Financial Officer | 2026-06-01 | A | 11,006 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-01 | D | 11,006 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-01 | A | 11,006 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-02 | D | 4,866 | 15 | 75,374 | Common | Form 4 ↗ |
| Jill McConnell | Chief Financial Officer | 2026-06-02 | D | 4,866 | 15 | 75,374 | Common | Form 4 ↗ |
| Erin L. Russell | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erin L. Russell | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erin L. Russell | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Dr. Amrit Ray | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Amrit Ray | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-06-10 | D | 4,674 | 17 | 78,617 | Common | Form 4 ↗ |
| Edward Pesicka | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Pesicka | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | D | 18,244 | 16 | 298,107 | Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-06-10 | D | 38,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-06-10 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| William Sharbaugh | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Amrit Ray | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Pesicka | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter M. Neupert | Director | 2026-06-10 | A | 12,852 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Smith | Director | 2026-07-20 | A | 6,598 | 0 | 0 | Common | Form 4 ↗ |
| Machelle Sanders | Director | 2026-08-03 | D | 9,700 | 18 | 174,697 | Common | Form 4 ↗ |
| David Smith | Director | 2026-08-03 | A | 15,840 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-04 | D | 416,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-04 | A | 416,666 | 0 | 0 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-05 | D | 50,417 | 19 | 972,040 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-05 | D | 49,452 | 19 | 941,072 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-06 | D | 55,975 | 18 | 1,010,909 | Common | Form 4 ↗ |
| Anshul Thakral | Director | 2026-08-06 | D | 55,882 | 18 | 1,015,376 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-08-18 | D | 11,313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-08-18 | A | 11,313 | 0 | 0 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-08-19 | D | 4,892 | 18 | 88,985 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-09-08 | D | 7,157 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-09-08 | A | 7,157 | 0 | 0 | Common | Form 4 ↗ |
| Erin L. Russell | Interim CAO | 2026-09-08 | D | 850 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erin L. Russell | Interim CAO | 2026-09-08 | A | 850 | 0 | 0 | Common | Form 4 ↗ |
| Erin L. Russell | Interim CAO | 2026-09-09 | D | 246 | 17 | 4,145 | Common | Form 4 ↗ |
| Mark Morais | Chief Operating Officer | 2026-09-09 | D | 3,149 | 17 | 53,061 | Common | Form 4 ↗ |
| Jason Fredrick Knoblauch | Chief Financial Officer | 2026-09-10 | A | 144,434 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (103 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Anshul Thakral. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 40. As printed: 11,584,483. View filing ↗
- Section 01, Thomas Pike. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 40. As printed: 7,791,722. View filing ↗
- Section 01, Jill McConnell. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 40. As printed: 1,680,873. View filing ↗
- Section 01, Mark Morais. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 40. As printed: 1,616,788. View filing ↗
- Section 01, Peter Neupert. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 40. As printed: 1,145,261. View filing ↗
- Section 03, Jill McConnell PSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Morais PSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Neupert RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Pike RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anshul Thakral PSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jill McConnell PSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Morais PSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anshul Thakral RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jill McConnell RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Morais RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jill McConnell RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Morais RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-27. Section “CEO Pay Ratio”. As printed: 196 : 1. View filing ↗
- Section 08, Erin L. Russell. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 502,500. View filing ↗
- Section 08, Dr. Amrit Ray. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 340,000. View filing ↗
- Section 08, David Smith. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 317,466. View filing ↗
- Section 08, Machelle Sanders. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 310,000. View filing ↗
- Section 08, Edward Pesicka. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 300,000. View filing ↗
- Section 08, R. Andrew Eckert. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 75,000. View filing ↗
- Section 08, William Sharbaugh. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 22,500. View filing ↗
- Section 08, Anshul Thakral. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Thomas Pike. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Peter M. Neupert. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Peter M. Neupert 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter M. Neupert 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Parks 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill McConnell 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill McConnell 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill McConnell 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erin L. Russell 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erin L. Russell 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erin L. Russell 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Amrit Ray 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Amrit Ray 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Pesicka 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Smith 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Pesicka 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Smith 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Smith 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Machelle Sanders 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Smith 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Machelle Sanders 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Machelle Sanders 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Sharbaugh 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Amrit Ray 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Pesicka 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter M. Neupert 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Smith 2026-07-20. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Machelle Sanders 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Smith 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Thakral 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Thakral 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Thakral 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Thakral 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Thakral 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Thakral 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-08-19. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erin L. Russell 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erin L. Russell 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Erin L. Russell 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Morais 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Fredrick Knoblauch 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 94.82% (votes for as printed: 73,544,293). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 95.13% (votes for as printed: 68,050,281). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-16. Item 5.07 · say-on-pay result. As reported: 91.67% (votes for as printed: 71,701,466). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 607,466 + equity 1,260,000 + all other 0 = 1,867,466, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- Bausch + Lomb Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Bausch + Lomb Corporation's own proxy. As printed: 32,194,326. View filing ↗
- Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
- Organon & Co., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Organon & Co.'s own proxy. As printed: 15,813,296. View filing ↗
- Charles River Laboratories International, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Fortrea Holdings Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Fortrea Holdings Inc.'s own proxy. As printed: 11,584,483. View filing ↗
- Medpace Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. View filing ↗
- QuidelOrtho Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. View filing ↗
- Sotera Health Company, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. View filing ↗
- Integra LifeSciences, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences's own proxy. As printed: 9,375,551. View filing ↗
- Enovis Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Enovis Corporation's own proxy. As printed: 9,242,161. View filing ↗
- Perrigo Company plc, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Perrigo Company plc's own proxy. As printed: 9,042,603. View filing ↗
- Dentsply Sirona Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dentsply Sirona Inc.'s own proxy. As printed: 8,760,139. View filing ↗
- Bio-Rad Laboratories, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bio-Rad Laboratories's own proxy. As printed: 7,995,841. View filing ↗
- Alkermes plc, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. View filing ↗
- Conmed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Conmed Corporation's own proxy. As printed: 7,634,873. View filing ↗
- Teleflex Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. View filing ↗
- Bruker Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. View filing ↗
- Section 10a, Charles River Laboratories International, Inc. reciprocity. DEF 14A. Charles River Laboratories International, Inc. names Fortrea Holdings Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Medpace Holdings, Inc. reciprocity. DEF 14A. Medpace Holdings, Inc. names Fortrea Holdings Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, QuidelOrtho Corporation reciprocity. DEF 14A. QuidelOrtho Corporation names Fortrea Holdings Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗